To assess the safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression through an observational, multicenter Study - IMPRESS

开始日期2025-07-02

申办/合作机构

Torrent Pharmaceuticals Ltd.

TCTR20240809003 / Not yet recruiting临床1期

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Vortioxetine 20 mg Film-coated Tablets and Reference Product (Brintellix 20 mg film-coated tablets) in Healthy Thai Volunteers under Fasting Conditions

开始日期2024-11-13

申办/合作机构-

NCT06604520 / Not yet recruiting临床2期IIT

Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia

The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:
1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?
2. Do mood symptoms and cognition improve following treatment with vortioxetine?
Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment.
Participants will:
* Undergo a screening visit that involves clinical assessments and laboratory tests
* Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine
* Undergo memory and problem-solving tests before starting treatment with vortioxetine
* Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist
* Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine

开始日期2024-11-01

申办/合作机构

The Johns Hopkins University

[+1]

100 项与 SERT x 5-HT1D receptor x 5-HT1A receptor x 5-HT1B receptor x 5-HT3 receptor x 5-HT7 receptor 相关的临床结果

登录后查看更多信息

100 项与 SERT x 5-HT1D receptor x 5-HT1A receptor x 5-HT1B receptor x 5-HT3 receptor x 5-HT7 receptor 相关的转化医学

登录后查看更多信息

0 项与 SERT x 5-HT1D receptor x 5-HT1A receptor x 5-HT1B receptor x 5-HT3 receptor x 5-HT7 receptor 相关的专利（医药）

登录后查看更多信息

项与 SERT x 5-HT1D receptor x 5-HT1A receptor x 5-HT1B receptor x 5-HT3 receptor x 5-HT7 receptor 相关的文献（医药）

2016-06-01·L'Encéphale4区 · 医学

Les bases de pharmacologie fondamentale du système sérotoninergique : application à la réponse antidépressive

4区 · 医学

Review

作者: Gardier, A M ; David, D J

If serotonin (5-hydroxytryptamin [5-HT]) is well known for its role in mood regulation, it also impacts numerous physiological functions at periphery. Serotonin is synthetized at the periphery into the gut by intestinal enterochromaffin cells and in the central nervous system (CNS) in the raphe nucleus from the essential amino acid tryptophan. Physiological effects of 5-HT are mediated by about 15 serotoninergic receptors grouped into seven broad families (5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7 receptor families). Except 5-HT3 receptor, a ligand-gated ion channels, all the others are G protein-coupled receptors. Serotonin's homeostasis involves serotoninergic autoreceptor such as 5-HT1A, 5-HT1B, 5-HT1D, the enzymatic degradation of serotonin by monoamine oxidase A (MAO-A), and a transporter (serotoninergic transporter [SERT]). In the CNS, the SERT is a key target for various antidepressant drugs such as Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin Norepinephrin Reuptake Inhibitors (SNRI) and tricyclics family. However, antidepressant activity of SERT inhibitors is not directly mediated by the SERT inhibition, but a consequence of postsynaptic 5-HT receptor activation following the increase in 5-HT levels in the synaptic cleft. In pharmacology, SSRIs are defined as indirect agonist of postsynaptic receptor. Among all the 5-HT receptors, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2B and 5-HT4 receptors activation would mediate antidepressant effects. In the meanwhile, 5-HT2A, 5-HT2C, 5-HT3, 5-HT6 and 5-HT7 receptors activation would induce opposite effects. The best serotoninergic antidepressant would directly activate 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2B and 5-HT4 and would block 5-HT2A, 5-HT2C, 5-HT3, 5-HT6 and 5-HT7 receptor. If the chemical synthesis of such a compound may be compromised, SERT inhibition associated with the blockade of some but not all 5-HT receptor could shorten onset of action and/or improve antidepressant efficacy on the overall symptomatology of depression.